Modern cancer therapy offers the greatest chance to patients to beat their cancer, however, some of the established therapies are associated with cardiac toxicities. Similarly, some of the new, targeted chemotherapeutic agents can affect heart function or the electrical conduction system of the heart. The Cardio-Oncology Program at Yale School of Medicine was one of the first programs in the nation developed to address the unique cardiovascular problems faced by patients with cancer and focuses on three important areas:
- Addressing the cardiac complications of cancer as well as the cardiac complications of cancer therapy,
- Treating patients with coexisting heart disease and cancer, and
- Providing presurgical and prechemotherapeutic cardiovascular risk assessment.